Evolent Health, Inc. beat EPS estimates 75% of the time across 16 reported quarters (12 beats, 4 misses), averaging +19.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.10 | $-0.11 | -10.0% | Miss | |
| Q1 FY26 | $-0.15 | $-0.12 | +20.0% | Beat | |
| Q4 FY25 | not reported | $0.06 | not reported | not reported | |
| Q3 FY25 | $0.00 | $-0.08 | not reported | Miss | |
| Q2 FY25 | $0.00 | $-0.17 | not reported | Miss | |
| Q1 FY25 | not reported | $-0.04 | not reported | not reported | |
| Q4 FY24 | not reported | $0.03 | not reported | not reported | |
| Q3 FY24 | not reported | $-0.08 | not reported | not reported | |
| Q2 FY24 | $0.12 | $0.19 | +58.3% | Beat | |
| Q1 FY24 | $0.12 | $0.16 | +33.3% | Beat | |
| Q4 FY23 | not reported | $0.15 | not reported | not reported | |
| Q3 FY23 | $0.00 | $0.19 | not reported | Beat |
Back to EVH overview · EVH holders · EVH KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.